SFM
ONCT

Soros Fund Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Soros Fund Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-28
Closed -$54K – 364
2014
Q2 		$54K Buy
+28
New +$55.4K ﹤0.01% 352

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Soros Fund Management's ONCT Position: Q3 2014 in Review

Soros Fund Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2014, closing a stake of 28 shares — an estimated $54K sold.

Soros Fund Management first reported a position in ONCT in Q2 2014 and held it in 1 quarter. The position peaked at $54K in Q2 2014. 38 funds tracked by Wall St. Rank hold ONCT as of Q3 2014.

  • Soros Fund Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Soros Fund Management sold 28 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $54K.
  • Soros Fund Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • Soros Fund Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $54K in Q2 2014.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Soros Fund Management's 13F filing for Q3 2014, filed 14 Nov 2014.